Lipella Pharmaceuticals Inc. Common Stock (LIPO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Lipella Pharmaceuticals Inc. Common Stock (LIPO) has a cash flow conversion efficiency ratio of -1584.949x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.36 Billion) by net assets ($1.49 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of Lipella Pharmaceuticals Inc. Common Stoc to measure how much of total assets are equity-financed.
Lipella Pharmaceuticals Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Lipella Pharmaceuticals Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Lipella Pharmaceuticals Inc. Common Stoc (LIPO) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
Lipella Pharmaceuticals Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lipella Pharmaceuticals Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
LEPU MED.T.B. SP.GDR O.N.
F:07Z0
|
N/A |
|
I.Ceram SA
PA:ALICR
|
0.094x |
|
LMS Capital Plc
LSE:LMS
|
-0.042x |
|
Xeros Technology Group Plc
LSE:XSG
|
-1.072x |
|
Meyer Burger Tech AG
SW:MBTN
|
-0.961x |
|
Braime Group PLC
LSE:BMT
|
0.088x |
|
Prospex Energy PLC
LSE:PXEN
|
-0.052x |
|
Kukbo Co. Ltd.
KO:001140
|
0.946x |
Annual Cash Flow Conversion Efficiency for Lipella Pharmaceuticals Inc. Common Stock (2019–2024)
The table below shows the annual cash flow conversion efficiency of Lipella Pharmaceuticals Inc. Common Stock from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see LIPO market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.92 Million | $-3.95 Million | -2.058x | -105.45% |
| 2023-12-31 | $3.14 Million | $-3.15 Million | -1.002x | -155.80% |
| 2022-12-31 | $4.68 Million | $-1.83 Million | -0.392x | +43.64% |
| 2021-12-31 | $1.42 Million | $-989.27K | -0.695x | -1026.69% |
| 2020-12-31 | $463.32K | $-28.58K | -0.062x | -118.66% |
| 2019-12-31 | $-118.34K | $-39.12K | 0.331x | -- |
About Lipella Pharmaceuticals Inc. Common Stock
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It develops LP-10, a formulation of tacrolimus for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen plan… Read more